Structure-based prediction of human intestinal membrane permeability for rapid in silico BCS classification

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 6, 2013, Pages 321-335

  Sun, Le ^a   Liu, Xiaohong ^a   Xiang, Rongwu ^a   Wu, Chunnuan ^a   Wang, Yongjun ^a   Sun, Yinghua ^a   Sun, Jin ^a   He, Zhonggui ^a  

^a School of Pharmacy   (China)

Author keywords

BCS; computational ADME; human effective intestinal membrane permeability; multivariate analysis; QSPR

Indexed keywords

AZTREONAM; CAPTOPRIL; CARVEDILOL; CHLORAMPHENICOL; CODEINE; COLCHICINE; CROMOGLYCATE DISODIUM; DOMPERIDONE; ERYTHROMYCIN; GLIPIZIDE; GLIQUIDONE; LEVOTHYROXINE; LINCOMYCIN; METFORMIN; METOPROLOL; PENICILLAMINE; PROMETHAZINE; PYRIDOSTIGMINE; RANITIDINE; TIMOLOL; TOLBUTAMIDE; ZIDOVUDINE;

ARTICLE; BIOPHARMACEUTICAL CLASSIFICATION SYSTEM; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; HEALTH CARE SYSTEM; LIPOPHILICITY; MAXIMUM PERMISSIBLE DOSE;

BCS; COMPUTATIONAL ADME; HUMAN EFFECTIVE INTESTINAL MEMBRANE PERMEABILITY; MULTIVARIATE ANALYSIS; QSPR;

CELL MEMBRANE PERMEABILITY; HUMANS; INTESTINAL ABSORPTION; INTESTINES; LINEAR MODELS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84883739772     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1848     Document Type: Article

References (47)

1. Ruiz-Garcia A, Bermejo M, Moss A, et al,. Pharmacokinetics in drug discovery. J Pharm Sci 2008; 97: 654-690. doi: 10.1002/jps.21009.
2. Lipinski CA, Lombardo F, Dominy BW, et al,. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26. DOI: S0169-409X(00)00129-0 [pii].
3. Veber DF, Johnson SR, Cheng HY, et al,. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002; 45: 2615-2623. DOI: jm020017n [pii].
4. Kola I, Landis J,. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-715. DOI: 10.1038/nrd1470nrd1470 [pii].
5. Fagerholm U,. The role of permeability in drug ADME/PK, interactions and toxicity-presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans. Pharm Res 2008; 25: 625-638. doi: 10.1007/s11095-007-9397-y.
6. Sugano K, Nabuchi Y, Machida M, et al,. Prediction of human intestinal permeability using artificial membrane permeability. Int J Pharm 2003; 257: 245-251. DOI: S0378517303001613 [pii].
7. Knutson T, Fridblom P, Ahlstrom H, et al,. Increased understanding of intestinal drug permeability determined by the loc-i-gut approach using multislice computed tomography. Mol Pharm 2009; 6: 2-10. DOI: 10.1021/mp800145r [pii] 10.1021/mp800145r.
8. Lennernas H., Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007; 37: 1015-1051. DOI: 83594885[pii] 10.1080/00498250701704819.
9. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, et al,. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci 2007; 10: 368-379.
10. Castella ME, Reist M, Mayer JM, et al,. Development of an in vitro rat intestine segmental perfusion model to investigate permeability and predict oral fraction absorbed. Pharm Res 2006; 23: 1543-1553. DOI: 10.1007/s11095-006-0249- y.
11. Fagerholm U, Johansson M, Lennernas H,. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996; 13: 1336-1342.
12. Avdeef A, Nielsen PE, Tsinman O,. Pampa-a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates. Eur J Pharm Sci 2004; 22: 365-374. DOI: 10.1016/j.ejps.2004.04.009S0928098704001216 [pii].
13. Sugano K., Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug-like molecule population. Int J Pharm 2009; 373: 55-61. DOI: S0378-5173(09)00068-4 [pii] 10.1016/j.ijpharm.2009.02.002.
14. Di Fenza A, Alagona G, Ghio C, et al,. Caco-2 cell permeability modelling: a neural network coupled genetic algorithm approach. J Comput Aided Mol Des 2007; 21: 207-221. DOI: 10.1007/s10822-006-9098-3.
15. Sun D, Lennernas H, Welage LS, et al,. Comparison of human duodenum and caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 2002; 19: 1400-1416.
16. Winiwarter S, Bonham NM, Ax F, et al,. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 1998; 41: 4939-4949. DOI: 10.1021/jm9810102jm9810102 [pii].
17. Refsgaard HH, Jensen BF, Brockhoff PB, et al,. In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem 2005; 48: 805-811. doi: 10.1021/jm049661n.
18. Winiwarter S, Ax F, Lennernas H, et al,. Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J Mol Graph Model 2003; 21: 273-287. DOI: S1093-3263(02)00163-8 [pii].
19. Dahan A, Lennernas H, Amidon GL, et al,. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm 2012; 9: 1847-1851. doi: 10.1021/mp300140h.
20. Hou T, Wang J, Zhang W, et al,. ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. J Chem Inf Model 2007; 47: 208-218. doi: 10.1021/ci600343x.
21. Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA 2000.
22. Lindenberg M, Kopp S, Dressman JB,. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58: 265-278. DOI: 10.1016/j.ejpb.2004.03.001S0939641104000438 [pii].
23. Li H, Sun J, Wang Y, et al,. Structure-based in silico model profiles the binding constant of poorly soluble drugs with beta-cyclodextrin. Eur J Pharm Sci 2011; 42: 55-64. DOI: S0928-0987(10)00351-9 [pii] 10.1016/j.ejps.2010.10. 006.
24. Lentz KA, Polli JW, Wring SA, et al,. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res 2000; 17: 1456-1460.
25. Database: drugbank.
26. Sridevi S, Diwan PV,. Effect of pH and complexation on transdermal permeation of gliquidone. Pharmazie 2002; 57: 632-634.
27. Egan WJ, Lauri G,. Prediction of intestinal permeability. Adv Drug Deliv Rev 2002; 54: 273-289. DOI: S0169409X02000042 [pii].
28. Gram LK, Rist GM, Lennernas H, et al,. Impact of carriers in oral absorption: Permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide. Eur J Pharm Sci 2009; 37: 378-386.
29. Shitara Y, Sugiyama D, Kusuhara H, et al,. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res 2002; 19: 147-153.
30. Takagi T, Ramachandran C, Amidon GL, et al,. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 2006; 3: 631-643. doi: 10.1021/mp0600182.
31. Varma MV, Gardner I, Kattan AF, et al,. pH-dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDS) in early drug discovery. Mol Pharm 2012; 9: 1199-1212.
32. Wu X, George RL, Ganapathy V, et al,. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta 2000; 1466: 315-327.
33. Patutina OA, Mironova NL, Logashenko EB, et al,. Cyclophosphamide metabolite inducing apoptosis in RLS mouse lymphosarcoma cells is a substrate for P-glycoprotein. Bull Exp Biol Med 2012; 152: 348-352.
34. Takara K, Kakumoto M, Okumura K, et al,. Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci 2002; 70: 1491-1500.
35. Vollrath V, Wielandt AM, Chianale J, et al,. Effect of colchicine and heat shock on multidrug resistance gene and P-glycoprotein expression in rat liver. J Hepatol 1994; 21: 754-763.
36. Westholm DE, Stenehjem DD, Rumbley JN, et al,. Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology 2009; 150: 1025-1032.
37. Brustle M, Beck B, Schindler T, et al,. Descriptors, physical properties, and drug-likeness. J Med Chem 2002; 45: 3345-3355. DOI: jm011027b [pii].
38. Avdeef A, Tam KY,. How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability. J Med Chem 2010; 53: 3566-3584.
39. Fong SY, Liu M, Wei H, et al,. Establishing the pharmaceutical quality of Chinese Herbal medicine: a provisional BCS classification. Mol Pharm 2013; 10 (5): 1623-1643.
40. Paintaud G, Alvan G, Svensson JO, et al,. Nonlinearity of amoxicillin absorption kinetics in human. Eur J Clin Pharmacol 1992; 43: 283-288.
41. Lennernas H,. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Pharm Res 1995; 12: 1573-1582.
42. Nakashima E, Tsuji A, Yamana T, et al,. Intestinal absorption mechanism of amino-beta-lactam antibiotics. III. Kinetics of carrier-mediated transport across the rat small intestine in situ. J Pharmacobiodyn 1984; 7: 452-464.
43. Cvetkovic M, Leake B, Kim RB, et al,. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866-871.
44. Lennernas H, Nilsson D, Paalzow L, et al,. The effect of l -leucine on absorption of Levodopa, studied by regional jejuna perfusion in man. Br J Clin Pharmacol 1993; 35: 243-250.
45. Hidalgo IJ, Borchardt RT,. Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2. Biochim Biophys 1990; 1028: 25-30.
46. Ganapathy ME, Huang W, Leibach FH, et al,. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 1998; 246: 470-475.
47. Sandstrom R, Karlsson A, Lennernas H, et al,. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 1998; 15: 856-862.